Evidence map›Paper›PMID 26380176›Full record

ReviewTranslational lung cancer research2015

Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Robert J Optican, Caroline Chiles

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Ultrasound location of ground-glass opacity during thoracoscopic surgery.Interactive cardiovascular and thoracic surgery · 2022
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert J Optican1 Department of Radiology, Baptist Memorial Hospital, Memphis, TN 38120, USA ; 2 Department of Radiology, Wake Forest Health Sciences Center, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Caroline Chiles1 Department of Radiology, Baptist Memorial Hospital, Memphis, TN 38120, USA ; 2 Department of Radiology, Wake Forest Health Sciences Center, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization estimates that, in 2012, there were 1,589,925 deaths from lung cancer worldwide. Screening for lung cancer with low-dose computed tomography (LDCT) has the potential to significantly alter this statistic, by identifying lung cancers in earlier stages, enabling curative treatment. Challenges remain, however, in replicating the 20% mortality benefit demonstrated by the National Lung Screening Trial (NLST), in populations outside the confines of a research trial, not only in the US but around the world. We review the history of lung cancer screening, the current evidence for LDCT screening, and the key elements needed for a successful screening program.

Indexed as

computed tomographyLung cancerlung cancer screening

Identifiers

PMID26380176
PMCPMC4549464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.